“…Yalan Dai et al elucidated that vemurafenib inhibits the immune escape biomarker BCL2A1 by targeting the PI3K/AKT signaling pathway to suppress breast cancer [ 14 ]. BINGNAN REN et al showed that siBRAF inhibits the PI3K/AKT/mTOR signaling pathway synergistically, reducing biological activity while increasing chemosensitivity in non-small cell lung cancer (NSCLC) cells [ 15 ]. However, the precise effect of BRAF on the occurrence and development of ATC remains unknown.…”